Review Article Conventional Treatments plus Acupuncture for Asthma in Adults and Adolescent: A Systematic Review and Meta-Analysis

Chunxiang Jiang,¹ Lanlan Jiang,² and Qingwu Qin ^{1,3,4}

¹Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China

²Department of Pulmonary and Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China ³Hunan Diagnosis and Treatment Center of Respiratory Disease, Changsha, Hunan 410011, China

⁴Research Unit of Respiratory Disease, Central South University, Changsha, Hunan 410011, China

Correspondence should be addressed to Qingwu Qin; qinqingwu@csu.edu.cn

Received 15 October 2018; Revised 21 December 2018; Accepted 31 December 2018; Published 17 January 2019

Academic Editor: Alfredo Vannacci

Copyright © 2019 Chunxiang Jiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. The efficacy of conventional treatments plus acupuncture for asthma in adult and adolescent is uncertain. Literature reports are conflicting; therefore, the aim of this study was to determine the efficacy of conventional treatments plus acupuncture versus conventional treatments alone using a meta-analysis of all published randomized clinical trials (RCTs). *Methods.* Two reviewers independently performed a comprehensive literature search from multiple electronic sources (1990–2018), including PubMed, EMBASE, the Cochrane Library, Web of Science, China National Knowledge Infrastructure, and WanFang databases. RCTs in which adult and adolescent patients with asthma (age \geq 12 years) were divided into conventional treatments plus acupuncture as a complementary therapy could improve the symptom response rate (OR = 7.87, 95% CI = [4.13, 14.99], p < 0.00001) and significantly decrease interleukin-6 (IL-6) levels (MD = -11.42; 95% CI = [-15.28, -7.56], p < 0.00001). However, indices of pulmonary function, including the forced expiratory volume in one second (FEV₁) (MD = 0.22, 95% CI = [-0.11, 0.56], p = 0.19) and FEV₁/forced vital capacity (FVC) (MD = 8.62, 95% CI = [-0.35, 17.59], p = 0.06), failed to be improved with conventional treatments plus acupuncture. *Conclusion.* Conventional treatments plus acupuncture are associated with significant benefits for adult and adolescent patients with asthma. Therefore, we suggest the use of conventional treatments plus acupuncture for asthma patients.

1. Introduction

Asthma is one of the most common chronic diseases with a multifactorial etiology that is characterized by chronic airway inflammation, hyperresponsiveness, and reversible airway obstruction, affecting approximately 358 million people worldwide [1–3]. Over the past few decades, the global prevalence, mortality, morbidity, and economic burden of asthma have increased [3–10]. The treatment response for a particular patient may be difficult to predict due to the heterogeneous nature of asthma [11, 12].

Despite the availability of clinical practice guidelines and standard-of-care therapy, a large proportion of asthma patients have a poor quality-of-life [13, 14]. Meanwhile, the majority of the currently available therapeutic approaches, such as muscle relaxants and anti-inflammatory drugs, cannot change the natural course of asthma [15].

Therefore, a high unmet requirement for novel asthma therapeutics is necessary, especially for those with severe disease. Many asthma patients turn to complementary or alternative therapies to improve their conditions. In China, acupuncture has been used to manage asthma for thousands of years. Asthma was listed as an indication for acupuncture in 1979 by the World Health Organization (WHO) [16] and has been recommended as an adjunctive treatment in comprehensive management programs for asthma by the US National Institutes of Health.

Several clinical trials have reported both beneficial and detrimental effects from acupuncture for the treatment of asthma [17–19]. This may be caused by differences in trial

design, treatment mode, or the small size of the trials. Previous systematic reviews [20] and meta-analyses have reported the effect of acupuncture. However, most of the studies included randomized clinical trials (RCTs) comparing real and sham acupuncture in asthma patients, which has little instructive significance for clinical treatment as acupuncture is often used as a complement to conventional therapy.

Therefore, in this meta-analysis, RCTs comparing conventional treatments plus acupuncture with conventional treatments alone in asthma patients were included to determine the effect of acupuncture as a supportive therapy.

2. Methods and Materials

2.1. Search Strategy. Two reviewers independently performed a comprehensive literature search from multiple electronic sources, including PubMed, EMBASE, the Cochrane Library, Web of Science, China National Knowledge Infrastructure, and the WanFang databases between Jan. 1, 1990, and June 1, 2018. The following search terms were used: (acupuncture therapy, acupuncture, needling therapy, needling) and (bronchial asthma, asthma, asthmatic) to identify relevant papers. The terms were combined appropriately with medical subheading terms and appropriately adjusted for different databases. For example, ((((((acupunture therapy) OR acupuncture) OR needling therapy) OR needling) OR "Acupunture Therapy" [MeSH]))) AND ((((bronchial asthma) OR asthma) OR asthmatic)) AND ((("Randomized Controlled Trial" [Publication Type] OR "Randomized Controlled Trials as Topic" [MeSH])) OR random*))) Filters: Publication date from 1990/01/01 to 2018/06/01. The detailed search strategy is provided in supplementary materials (available here).

2.2. Study Selection

2.2.1. Inclusion Criteria for Studies. (1) RCTs were published in English or Chinese, with the full text available.

(2) Included patients met the diagnostic criteria for bronchial asthma.

(3) RCTs compared conventional treatments plus acupuncture with conventional treatments alone.

(4) Studies measured at least one of the following end points: symptom response rate, forced expiratory volume in one second (FEV1), FEV₁/forced vital capacity (FVC), and interleukin-6 (IL-6) levels.

2.2.2. Exclusion Criteria for Studies. (1) Studies only involved cells or animals or were case reports, letters, reviews, observational studies, or nonrandomized clinical trials.

(2) Included patients were children younger than 12 years of age.

(3) Trials in which acupuncture therapies were used with other therapies.

2.2.3. Data Extraction and Management. The extraction table was designed according to the Cochrane manual. Identified

publications from databases were independently screened by two authors to exclude the irrelevant studies. Controversial opinions were resolved by discussion.

2.3. Bias Assessment of the Included Studies. Risk of bias was assessed using the Cochrane classification for the following seven criteria: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias.

2.4. Statistical Analysis. The data were analyzed using Revman 5.3 and Stata 14.0 software. The results were presented as the mean difference (MD) or odds ratio (OR) and 95% confidence intervals (95% CI). To analyze data without obvious heterogeneity (p > 0.1 and $I^2 < 50\%$) the fixed-effects model was used; otherwise, the random-effects model was used. If possible, heterogeneity was investigated and subgroup analysis was conducted. Sensitivity analysis was also performed to evaluate the influence of an individual study on the final effect. To evaluate publication bias, Egger's test was used. A p value < 0.05 was considered statistically significant.

3. Results

3.1. Literature Selection. The flow diagram of the literature identification and selection process is shown in Figure 1. A total of 1242 studies were identified, and 392 studies were excluded owing to duplication. After reading the titles and abstracts, 776 studies were excluded. The full-length texts of 74 candidate studies were carefully reviewed, of which 65 studies were excluded, including 10 reviews/meta-analyses, 9 studies without a control group, 5 studies with duplicated data, 32 studies involving acupuncture versus medicine, 5 studies with data that could not be extracted, and 4 studies only including animal experiments. Finally, nine trials were included in the quantitative analysis. The characteristics of the nine included trials are shown in Table 1.

3.2. Qualitative Assessment of the Included Studies. Among the 9 studies, three studies [21–23] used random number table and one study [24] took computer program to generate random sequence. The remaining 5 studies only mentioned "random" or "randomization". As it is very difficult to blind therapists to the use of acupuncture therapy, only patients and assessors were blinded. Only two studies [21, 24] reported the allocation concealment and blinding details. In addition, all the included studies had low risk of reporting bias. The results of bias are shown in Figures 2 and 3.

3.3. Response Rate. Among all nine included studies, five RCTs [22, 25–28] (including 472 patients) reported the response rates of the patients in the two groups. There was no significant heterogeneity (p = 0.58, $I^2 = 0\%$) among these RCTs, and our pooled results showed statistically significant effects of conventional treatments plus acupuncture compared with conventional treatments alone (OR = 7.87, 95%)

First author (year)	Sample size	Stage, levels of severity	Sex (F:M)	Study location	Patient age/ Duration of disease	Intervention	Control	Study design
Fu Yu (2014)	107	Chronic persistent, middle	A: 54:25 B: 18:10	Beijing, China	A: 51.82 ± 9.90 y B: 52.40 ± 9.18 y	Ventolin inhalant + Acupuncture (12 w)	Ventolin inhalant (12 w)	Al vs. A2 vs. A3 vs. B
Jiang Suqun (2012)	160	Acute	A: 37:43 B: 35:45	Hunan, China	A: 32.31 ± 9.32 y B: 34.21 ± 8.33 y	Bronchodilator + ICS + Antibiotics + Acupuncture (14 d) *	Bronchodilator + ICS + Antibiotics (14 d) *	A vs. B
Ju Kim (2013)	27	Chronic persistent	A: 8:5 B: 3:11	Jiangsu, China	A: 52.62 ± 14.16 y B: 57.14 ± 12.24 y	Ventolin inhalant + Acupuncture (12 w)	Ventolin inhalant (12 w)	A vs. B
Jun-Yong Choi (2010)	30	Chronic persistent	A: 7:8 B: 7:8	Korea	A: 48.27 ± 7.99 y B: 50.43 ± 12.64 y	Western medicine + Acupuncture (4 w)*	Western medicine (4 w)*	A vs. B vs. C
Lv Guifen (2012)	06	Chronic persistent	A: 17:13 B: 17:13	Shandong, China	A: 15–68 y B: 16–17 y	Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation ($50/250 \ \mu g$, Bid) + Acupuncture (4 w)	Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation (50/250 μ g, Bid, 4 w)	A vs. B vs. C
Wang Wenyan (2010)	70	Acute	A: 17:18 B: 18:17	Jilin, China	A: 15–65 y/2–15 y B: 14–69 y/2–13 y	Bronchodilator + ICS + Antibiotics + Acupuncture (10 d) *	Bronchodilator + ICS + Antibiotics (10 d) *	A vs. B
Zhang Wenpeng (2006)	104	Chronic persistent	A: 44:15 B: 33:12	Russia	A: 44.5 ± 13.9 y B: 44.2 ± 14.6 y	Western medicine + Acupuncture (12 d)**	Western medicine (12 d) * *	A vs. B
Zhu Dongxiao (2010)	66	Chronic persistent	A: 18:15 B: 20:13	Henan, China	A: 12–85 y B: 12–86 y	Beclomethasone Dipropionate Inhaler + Theophylline Sustained Release Tablets + Acupuncture * * *	Beclomethasone Dipropionate Inhaler + Theophylline Sustained Release Tablets * * *	A vs. B vs. C
Zhang Zhilong (2005)	06	Acute	A: 32:28 B: 16:14	Tianjin, China	A: 20–65 y/6–32 y B: 19–65 y/5–33 y	Terbutaline sulphate aerosol + Acupuncture (10 d)	Terbutaline sulphate aerosol (10 d)	A vs. B
A: conventions (SABA), theop *Specific drug **The details	ll treatments plus hylline, leukotrie s were not specifi re listed in Table	acupuncture; B: conventio ne receptor antagonist (LTI ed. :2.	aal treatments al XA), long-acting	one; Western medicir beta2-agonist (LABA	ie: any drug that is recoi (), inhaled corticosteroi	mmended by the Global Initiative Foi ds (ICS), and ICS/LABA.	r Asthma (GINA), including short-ac	ting beta2-agonist

TABLE 1: Characteristics of the included studies.

Evidence-Based Complementary and Alternative Medicine

Group	No drug	Cromolyn Sodium	Ventolin	Cromolyn Sodium + Ventolin	Aminophylline + Ventolin	Atrovent	Fenoterol	Beclomethasone Dipropionate	Beclomethasone Dipropionate + Ventolin	Beclomethasone Dipropionate + Fenoterol	Beclomethasone Dipropionate + Aminophylline
Intervention group	3	5	9	3	2	1	6	9	12	6	3
Control group	3	4	9	3	2	1	9	4	8	6	2
Note: the doses	of the drug	gs shown in the table a	re as follow	s: Cromolyn Sodium,	10 mg, four times per	r day (Qid); V	entolin, 0.1 mg	, Qid; Fenoterol, 0.21	mg, three times per d	ay (Tid); Beclometha	sone Dipropionate,

TABLE 2: Comparison of drugs used between the two groups.

Note: the goses of the grugs snown in the latter are as to unows. 250 mg, Tid, Arminophylline, 0.1 g, Tid, Atrovent, 40 μ g, Tid. * * * The course of treatment was not specified.



FIGURE 1: Flow chart for study selection.





CI = [4.13, 14.99], p < 0.00001) (Figure 4). Subgroup analyses also showed beneficial effects of conventional treatments plus acupuncture both in the chronic phase (OR = 10.33, 95% CI = [3.99, 26.73], p < 0.00001, heterogeneity: p = 0.84, $I^2 = 0\%$) and in the acute phase (OR = 6.40, 95% CI = [2.68, 15.31], p < 0.0001, heterogeneity: p = 0.35, $I^2 = 4\%$).

3.4. Parameters of Pulmonary Ventilation

3.4.1. FEV_1 . Five RCTs [22, 24, 27–29] (including 376 patients) compared the effects of conventional treatments plus acupuncture and the conventional treatments alone on FEV₁. There was significant heterogeneity among these RCTs



FIGURE 3: Summary of risk bias.

(p < 0.00001, $I^2 = 86\%$), a random-effects model was used, and the pooled data showed no difference in therapeutic effects on FEV₁ between the two groups (MD = 0.22, 95% CI = [-0.11, 0.56], p = 0.19) (Figure 5(a)). Subgroup analyses also showed no improvements in FEV₁ with acupuncture plus conventional therapy in the chronic phase (MD = -0.13, 95% CI = [-0.51, 0.25], p = 0.51, heterogeneity: p = 0.42, I^2 = 0%). However, the FEV₁ was improved with acupuncture plus conventional therapy in the acute phase (MD = 0.39, 95% CI = [0.05, 0.74], p = 0.03, heterogeneity: p = 0.0003, $I^2 = 88\%$).

3.4.2. FEV_1/FVC . The effects between conventional treatments plus acupuncture and conventional treatments alone were investigated in four studies [21, 27–29], including 364 patients. The meta-analysis of these four RCTs failed to show favorable effects of conventional treatments plus acupuncture

on FEV₁/FVC compared with the conventional treatments alone (MD = 8.62, 95% CI = [-0.35, 17.59], p = 0.06) (Figure 5(b)). Marked heterogeneity was observed in this mode (p < 0.00001, I^2 = 95%); therefore, the subgroups were further analyzed. The results showed no improvements in FEV₁/FVC with acupuncture plus conventional therapy in either the chronic phase (MD = 4.31; 95% CI = [-7.95, 16.56], p = 0.49, heterogeneity: p = 0.06, I^2 = 72%) or in the acute phase (MD = 12.29, 95% CI = [-1.67, 26.26], p = 0.08, heterogeneity: p < 0.00001, I^2 = 97%).

3.5. Cytokine Expression

3.5.1. *IL-6*. Two RCTs [23, 26] compared the effects of conventional treatments plus acupuncture and conventional treatments alone on IL-6 levels. No heterogeneity was found (p = 0.86, $I^2 = 0\%$), and the fixed-effects model showed that

Evidence-Based Complementary and Alternative Medicine

	Acupuncture + Med	licine	Medici	ne		Odds Ratio		Odds	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fixe	ed, 95% Cl	
1.1.1 chronic phase										
Lv Guifen 2012	30	30	27	30	5.8%	7.76 [0.38, 157.14]				
Zhang Wenpeng 2006	39	53	8	39	31.7%	10.79 [4.02, 29.01]				
Subtotal (95% CI)		83		69	37.4%	10.33 [3.99, 26.73]				
Total events	69		35							
Heterogeneity: Chi ² = 0.0	04, df = 1 (P = 0.84); I ²	= 0%								
Test for overall effect: Z	= 4.81 (P < 0.00001)									
1.1.2 acute phase										
Zhang Zhilong 2005	57	60	27	30	23.4%	2.11 [0.40, 11.15]			-	
Wang Wenyan 2010	34	35	28	35	10.4%	8.50 [0.99, 73.28]			•	_
Jiang Sugun 2012	77	80	59	80	28.8%	9.14 [2.60, 32.09]				
Subtotal (95% CI)		175		145	62.6%	6.40 [2.68, 15.31]				
Total events	168		114							
Heterogeneity: Chi ² = 2.0	08, df = 2 (P = 0.35); l ²	= 4%								
Test for overall effect: Z	= 4.17 (P < 0.0001)									
Total (95% CI)		258		214	100.0%	7.87 [4.13, 14.99]			•	
Total events	237		149							
Heterogeneity: Chi ² = 2.8	35, df = 4 (P = 0.58); l ²	= 0%								
Test for overall effect: Z	= 6.28 (P < 0.00001)						0.001	U.I Medicino	Acupupeture	1000 + Medicino
Test for subgroup differe	nces: Chi² = 0.53, df =	1 (P = 0).47), l² =	0%				weuchte	Acupuncture	weuchte

FIGURE 4: Efficacy of conventional treatments plus acupuncture on the response rate.

	OR Fluctuation	95% CI Fluctuation	Publication bias (P value)
Response rate	3.93-7.73	1.90–14.85	0.806

Note: p < 0.05 indicates that a publication bias exists.

Table 4: Summar	y of sensitivity :	inalysis of paramete	rs for FEV ₁ and	∃ FEV₁/FVC
-----------------	--------------------	----------------------	-----------------------------	------------

	MD Fluctuation	95% CI Fluctuation	Publication bias (P value)
FEV ₁	0.14-0.32	-0.23-0.65	0.144
FEV ₁ /FVC	5.86-11.34	-4.58-20.79	0.570

Note: p < 0.05 indicates that a publication bias exists.

the IL-6 level was significantly reduced with conventional treatments plus acupuncture (MD = -11.42, 95% CI = [-15.28, -7.56], p < 0.00001) (Figure 6).

3.6. Sensitivity Analysis and Publication Bias. Sensitivity analysis was also performed to evaluate the stability of the results. As fewer than three data sets were identified for IL-6 analysis, a different model was used for its sensitivity analysis, and the results were found to be stable. To test the sensitivity of parameters with more than three data sets, we excluded the included studies one by one, and the results were found to be stable. In addition, Egger's test was used for publication bias analysis, which showed no publication bias (Tables 3 and 4).

4. Discussion

Acupuncture has been applied to treat asthma for thousands of years in China. Asthma was listed as an indication for acupuncture in 1979 by the WHO [16]; however, despite its use for millennia, no strong evidence has demonstrated the beneficial efficiency of conventional treatments plus acupuncture compared with conventional treatments alone. Previous research has indicated that acupuncture downregulates the expression of proinflammatory proteins and upregulates the expression of anti-inflammatory proteins [30]. In our current meta-analysis, we pooled the data from nine studies together and demonstrated that conventional treatments plus acupuncture significantly improved the symptom response rate (OR = 7.87, 95% CI = [4.13, 14.99], p < 0.00001) and decreased IL-6 levels (MD = -11.42; 95% CI = [-15.28, -7.56], p < 0.00001), compared with conventional treatments alone. However, ventilation parameters including FEV₁ (MD = 0.22, 95% CI = [-0.11, 0.56], p = 0.19) and FEV₁/FVC (MD = 8.62, 95% CI = [-0.35, 17.59], p = 0.06) showed no improvements with conventional treatments plus acupuncture.

We have made efforts to perform a comprehensive analysis; however, some limitations must be recognized. First, significant heterogeneity was found for FEV₁ and FEV₁/FVC. Therefore, after checking the included papers and extracted data, subgroup analysis by asthma phase was used to explore the source of heterogeneity. However, subgroup analysis found that combinations of different phases

	Acupunc	ture + Mee	dicine	Ν	/ledicin	e		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Tota	I Mea	n SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
2.1.1 chronic phase									
Ju Kim 2013	-0.03	0.74	13	3 0.2	9 0.86	14	14.0%	-0.32 [-0.92, 0.28]	
Jun-Yong Choi, O. 2010	-0.07	0.83	15	5 -0.0	7 0.49	14	16.6%	0.00 [-0.49, 0.49]	
Subtotal (95% CI)			28	3		28	30.6%	-0.13 [-0.51, 0.25]	
Heterogeneity: Tau ² = 0.00 Test for overall effect: Z = 0); Chi² = 0.65 0.66 (P = 0.5	5, df = 1 (P 51)	= 0.42)	; I ² = 0°	%				
2.1.2 acute phase									
Jiang Sugun 2012	2.22	0.33	80) 1.5	6 0.33	80	25.2%	0.66 [0.56, 0.76]	-
Wang Wenyan 2010	0.4	0.59	35	5 0.2	2 0.43	35	22.8%	0.18 [-0.06, 0.42]	+=-
Zhang Zhilong 2005	0.7	0.79	60	0.4	1 0.62	30	21.4%	0.29 [-0.01, 0.59]	
Subtotal (95% CI)			175	5		145	69.4%	0.39 [0.05, 0.74]	•
Heterogeneity: Tau ² = 0.08 Test for overall effect: Z = 2	; Chi² = 16.3 2.24 (P = 0.0	30, df = 2 (03)	P = 0.00	003); l²	= 88%				
Total (95% CI)			203	3		173	100.0%	0.22 [-0.11, 0.56]	•
Heterogeneity: Tau ² = 0.11	; Chi² = 28.7	78, df = 4 (P < 0.00	001); F	² = 86%)		-	
Test for overall effect: Z =	1.32 (P = 0.1	19)		,.					-2 -1 U 1 2 Medicine Asymptotype Medicine
Test for subgroup difference	es: Chi ² = 3	.94, df = 1	(P = 0.0)	95), l² =	74.6%				Medicine Acupuncture + Medicine
							(a)		
							(a)		
		 I Mandini 		Ma	diaina			Maan Differences	Mana Differences
A	cupunctur	e + Medic		INIE	aicine			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total N	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Study or Subgroup 2.2.1 chronic phase	Mean	SD	Total N	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Study or Subgroup 2.2.1 chronic phase Fu Yu 2014	Mean	9.13	Total N	Mean -5.47	9.37	Total	Weight 26.9%	9.26 [5.25, 13.27]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 chronic phase Fu Yu 2014 Ju Kim 2013 Subtati (05%) Cl)	Mean 3.79 1.08	9.13 13.85	79 13	Mean -5.47 4.67	9.37 19.52	Total 28 14	Weight 26.9% 18.1%	9.26 [5.25, 13.27] -3.59 [-16.29, 9.11]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 chronic phase Fu Yu 2014 Ju Kim 2013 Subtotal (95% CI)	3.79 1.08	9.13 13.85	79 13 92	• Mean -5.47 4.67	9.37 19.52	Total 28 14 42	Weight 26.9% 18.1% 45.0%	9.26 [5.25, 13.27] -3.59 [-16.29, 9.11] 4.31 [-7.95, 16.56]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 chronic phase Fu Yu 2014 Ju Kim 2013 Subtotal (95% CI) Heterogeneity: Tau ² = 59.4 Test for overall effect: Z =	3.79 1.08 48; Chi ² = 3. 0.69 (P = 0.	9.13 13.85 58, df = 1 49)	79 13 92 (P = 0.0	Mean -5.47 4.67 6); I ² =	9.37 19.52 72%	Total 28 14 42	Weight 26.9% 18.1% 45.0%	 Wean Difference IV, Random, 95% Cl 9.26 [5.25, 13.27] -3.59 [-16.29, 9.11] 4.31 [-7.95, 16.56] 	IV, Random, 95% Cl
Study or Subgroup 2.2.1 chronic phase Fu Yu 2014 Ju Kim 2013 Subtotal (95% CI) Heterogeneity: Tau ² = 59.4 Test for overall effect: Z = 2.2.2 acute phase	3.79 1.08 18; Chi ² = 3. 0.69 (P = 0.	9.13 13.85 58, df = 1 49)	79 13 92 (P = 0.0	Mean -5.47 4.67 6); I² =	9.37 19.52 72%	Total 28 14 42	Weight 26.9% 18.1% 45.0%	Nean Difference IV, Random, 95% Cl 9.26 [5.25, 13.27] -3.59 [-16.29, 9.11] 4.31 [-7.95, 16.56]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 chronic phase Fu Yu 2014 Ju Kim 2013 Subtotal (95% CI) Heterogeneity: Tau ² = 59.4 Test for overall effect: Z = 2.2.2 acute phase Jiang Suqun 2012	Mean 3.79 1.08 48; Chi² = 3. 0.69 (P = 0. 24.9	9.13 13.85 58, df = 1 49) 5.78	79 13 92 (P = 0.0	Mean -5.47 4.67 6); I ² = 5.6	9.37 19.52 72% 6.02	Total 28 14 42 80	Weight 26.9% 18.1% 45.0%	Nean Difference IV, Random, 95% Cl 9.26 [5.25, 13.27] -3.59 [-16.29, 9.11] 4.31 [-7.95, 16.56] 19.30 [17.47, 21.13]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 chronic phase Fu Yu 2014 Ju Kim 2013 Subtotal (95% CI) Heterogeneity: Tau ² = 59.4 Test for overall effect: Z = 2.2.2 acute phase Jiang Suqun 2012 Wang Wenyan 2010	Mean 3.79 1.08 48; Chi² = 3. 0.69 (P = 0. 24.9 10.15	9.13 13.85 58, df = 1 49) 5.78 8.6	Total M 79 13 92 (P = 0.0 80 35	Mean -5.47 4.67 6); I² = 5.6 5.1	9.37 19.52 72% 6.02 8.72	Total 28 14 42 80 35	Weight 26.9% 18.1% 45.0% 28.1% 26.9%	Nean Difference IV, Random, 95% Cl 9.26 [5.25, 13.27] -3.59 [-16.29, 9.11] 4.31 [-7.95, 16.56] 19.30 [17.47, 21.13] 5.05 [0.99, 9.11]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 chronic phase Fu Yu 2014 Ju Kim 2013 Subtotal (95% CI) Heterogeneity: Tau ² = 59.4 Test for overall effect: Z = 2.2.2 acute phase Jiang Suqun 2012 Wang Wenyan 2010 Subtotal (95% CI)	Mean 3.79 1.08 48; Chi² = 3. 0.69 (P = 0. 24.9 10.15	9.13 13.85 58, df = 1 49) 5.78 8.6	Total M 79 13 92 (P = 0.0 80 35 115	Mean -5.47 4.67 6); I² = 5.6 5.1	9.37 19.52 72% 6.02 8.72	Total 28 14 42 80 35 115	Weight 26.9% 18.1% 45.0% 28.1% 26.9% 55.0%	Near Difference IV, Random, 95% CI 9.26 [5.25, 13.27] -3.59 [-16.29, 9.11] 4.31 [-7.95, 16.56] 19.30 [17.47, 21.13] 5.05 [0.99, 9.11] 12.29 [-1.67, 26.26]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 chronic phase Fu Yu 2014 Ju Kim 2013 Subtotal (95% Cl) Heterogeneity: Tau ² = 59.4 Test for overall effect: Z = 2.2.2 acute phase Jiang Suqun 2012 Wang Wenyan 2010 Subtotal (95% Cl) Heterogeneity: Tau ² = 98.5	Action Action	9.13 9.13 13.85 58, df = 1 49) 5.78 8.6 9.38, df = 1	Total N 79 13 92 (P = 0.00 80 35 115 (P < 0.1	Mean -5.47 4.67 6); I ² = 5.6 5.1 000001)	9.37 19.52 72% 6.02 8.72 ; 1 ² = 97	Total 28 14 42 80 35 115 7%	Weight 26.9% 18.1% 45.0% 28.1% 26.9% 55.0%	Near Difference IV, Random, 95% Cl 9.26 [5.25, 13.27] -3.59 [-16.29, 9.11] 4.31 [-7.95, 16.56] 19.30 [17.47, 21.13] 5.05 [0.99, 9.11] 12.29 [-1.67, 26.26]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 chronic phase Fu Yu 2014 Ju Kim 2013 Subtotal (95% CI) Heterogeneity: Tau ² = 59.4 Test for overall effect: Z = 2.2.2 acute phase Jiang Suqun 2012 Wang Wenyan 2010 Subtotal (95% CI) Heterogeneity: Tau ² = 98.5 Test for overall effect: Z =	Mean 3.79 1.08 48; Chi² = 3. 0.69 (P = 0. 24.9 10.15 95; Chi² = 35 1.73 (P = 0.	9.13 13.85 58, df = 1 49) 5.78 8.6 9.38, df = 1 08)	80 33 92 (P = 0.0) 80 35 115 (P < 0.1)	Mean -5.47 4.67 6); l ² = 5.6 5.1 00001)	9.37 19.52 72% 6.02 8.72 ; 1 ² = 97	Total 28 14 42 80 35 115 7%	Weight 26.9% 18.1% 45.0% 28.1% 26.9% 55.0%	Wean Difference IV, Random, 95% CI 9.26 [5.25, 13.27] -3.59 [-16.29, 9.11] 4.31 [-7.95, 16.56] 19.30 [17.47, 21.13] 5.05 [0.99, 9.11] 12.29 [-1.67, 26.26]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 chronic phase Fu Yu 2014 Ju Kim 2013 Subtotal (95% CI) Heterogeneity: Tau ² = 59.4 Test for overall effect: Z = 2.2.2 acute phase Jiang Suqun 2012 Wang Wenyan 2010 Subtotal (95% CI) Heterogeneity: Tau ² = 98.5 Test for overall effect: Z = Total (95% CI)	Acupunctur 3.79 1.08 1.08 48 ; Chi ² = 3. 0.69 (P = 0. 24.9 10.15 95 ; Chi ² = 3. 1.73 (P = 0.	9.13 13.85 58, df = 1 49) 5.78 8.6 9.38, df = 1 08)	80 35 13 92 92 92 92 92 92 93 94 95 115 <t< td=""><td>Mean -5.47 4.67 6); I² = 5.6 5.1 000001)</td><td>9.37 19.52 72% 6.02 8.72 ; 1² = 97</td><td>Total 28 14 42 80 35 115 7%</td><td>Weight 26.9% 18.1% 45.0% 28.1% 26.9% 55.0% 100.0%</td><td>Wean Difference IV, Random, 95% CI 9.26 [5.25, 13.27] -3.59 [-16.29, 9.11] 4.31 [-7.95, 16.56] 19.30 [17.47, 21.13] 5.05 [0.99, 9.11] 12.29 [-1.67, 26.26] 8.62 [-0.35, 17.59]</td><td>IV, Random, 95% Cl</td></t<>	Mean -5.47 4.67 6); I ² = 5.6 5.1 000001)	9.37 19.52 72% 6.02 8.72 ; 1 ² = 97	Total 28 14 42 80 35 115 7%	Weight 26.9% 18.1% 45.0% 28.1% 26.9% 55.0% 100.0%	Wean Difference IV, Random, 95% CI 9.26 [5.25, 13.27] -3.59 [-16.29, 9.11] 4.31 [-7.95, 16.56] 19.30 [17.47, 21.13] 5.05 [0.99, 9.11] 12.29 [-1.67, 26.26] 8.62 [-0.35, 17.59]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 chronic phase Fu Yu 2014 Ju Kim 2013 Subtotal (95% CI) Heterogeneity: Tau ² = 59.4 Test for overall effect: Z = 2.2.2 acute phase Jiang Suqun 2012 Wang Wenyan 2010 Subtotal (95% CI) Heterogeneity: Tau ² = 98.5 Test for overall effect: Z = Total (95% CI) Heterogeneity: Tau ² = 73.7	Acupunctur 3.79 1.08 1.08 $18; Chi^2 = 3.$ $0.69 (P = 0.)$ 24.9 10.15 $95; Chi^2 = 3.$ $1.73 (P = 0.)$ $70; Chi^2 = 60$	9.13 13.85 58, df = 1 49) 5.78 8.6 9.38, df = 1 08) 0.04, df = 3	Total N 79 13 92 ($P = 0.0$ (P = 0.0 35 115 (P < 0.1) 207 3 (P < 0.1)	Mean -5.47 4.67 6); I ² = 5.6 5.1 000001)	9.37 19.52 72% 6.02 8.72 ; 1 ² = 97	Total 28 14 42 80 35 115 7% 157 5%	Weight 26.9% 18.1% 45.0% 28.1% 26.9% 55.0% 100.0%	Wean Difference IV, Random, 95% CI 9.26 [5.25, 13.27] -3.59 [-16.29, 9.11] 4.31 [-7.95, 16.56] 19.30 [17.47, 21.13] 5.05 [0.99, 9.11] 12.29 [-1.67, 26.26] 8.62 [-0.35, 17.59]	TO Difference
Study or Subgroup 2.2.1 chronic phase Fu Yu 2014 Ju Kim 2013 Subtotal (95% CI) Heterogeneity: Tau ² = 59.4 Test for overall effect: Z = 2.2.2 acute phase Jiang Suqun 2012 Wang Wenyan 2010 Subtotal (95% CI) Heterogeneity: Tau ² = 98.5 Test for overall effect: Z = Total (95% CI) Heterogeneity: Tau ² = 73.7 Test for overall effect: Z =	Acupation Acupation 3.79 1.08 1.08 1.08 48 ; Chi ² = 3. 0.69 (P = 0. 24.9 10.15 95 ; Chi ² = 3. 1.73 (P = 0. 70 ; Chi ² = 60 1.88 (P = 0.	9.13 13.85 58, df = 1 49) 5.78 8.6 9.38, df = 1 0.8) 0.04, df = 3 0.04, df = 3	Total N 79 13 92 (P = 0.0) (P = 0.0) 80 35 115 (P < 0.0) 3 $(P < 0.0)$	Mean -5.47 4.67 6); I ² = 5.6 5.1 000001)	9.37 19.52 72% 6.02 8.72 ; 1 ² = 97	Total 28 14 42 80 35 115 7% 157 5%	Weight 26.9% 18.1% 45.0% 28.1% 26.9% 55.0% 100.0%	Wean Difference IV, Random, 95% CI 9.26 [5.25, 13.27] -3.59 [-16.29, 9.11] 4.31 [-7.95, 16.56] 19.30 [17.47, 21.13] 5.05 [0.99, 9.11] 12.29 [-1.67, 26.26] 8.62 [-0.35, 17.59]	-50 -25 0 25 50 Medicine Acupueturo + Medicine
Study or Subgroup 2.2.1 chronic phase Fu Yu 2014 Ju Kim 2013 Subtotal (95% CI) Heterogeneity: Tau ² = 59.4 Test for overall effect: Z = 2.2.2 acute phase Jiang Suqun 2012 Wang Wenyan 2010 Subtotal (95% CI) Heterogeneity: Tau ² = 98.5 Test for overall effect: Z = Total (95% CI) Heterogeneity: Tau ² = 73.7 Test for overall effect: Z = Test for overall effect: Z = Test for subgroup difference Test for subgroup difference	Action Action 3.79 1.08 1.08 1.08 48; Chi ² = 3. 0.69 (P = 0. 24.9 10.15 95; Chi ² = 38 1.73 (P = 0. 70; Chi ² = 60 1.88 (P = 0. 26: Chi ² = 60 1.88 (P = 0.	9.13 13.85 58, df = 1 49) 5.78 8.6 9.38, df = 1 0.04, df = 3 0.04, df = 3 0.01, df = 1	$\begin{array}{c} \textbf{Total N} \\ \textbf{Total N} \\ \textbf{79} \\ \textbf{13} \\ \textbf{92} \\ \textbf{(P = 0.0)} \\ \textbf{(P = 0.0)} \\ \textbf{35} \\ \textbf{115} \\ \textbf{(P < 0.)} \\ \textbf{36} \\ \textbf{(P < 0.)} \\ \textbf{36} \\ \textbf{(P = 0.)} \\ \textbf{(P = 0.)} \end{array}$	Mean -5.47 4.67 6); l ² = 5.6 5.1 000001) 000001) 40), l ² =	9.37 19.52 72% 6.02 8.72 ; 1 ² = 97 ; 1 ² = 95 = 0%	Total 28 14 42 80 35 115 7% 157 5%	Weight 26.9% 18.1% 45.0% 28.1% 26.9% 55.0% 100.0%	Wean Difference IV, Random, 95% CI 9.26 [5.25, 13.27] -3.59 [-16.29, 9.11] 4.31 [-7.95, 16.56] 19.30 [17.47, 21.13] 5.05 [0.99, 9.11] 12.29 [-1.67, 26.26] 8.62 [-0.35, 17.59]	-50 -25 0 25 50 Medicine Acupuncture + Medicine
Study or Subgroup 2.2.1 chronic phase Fu Yu 2014 Ju Kim 2013 Subtotal (95% CI) Heterogeneity: Tau ² = 59.4 Test for overall effect: Z = 2.2.2 acute phase Jiang Suqun 2012 Wang Wenyan 2010 Subtotal (95% CI) Heterogeneity: Tau ² = 98.6 Test for overall effect: Z = Total (95% CI) Heterogeneity: Tau ² = 73.7 Test for overall effect: Z = Test for subgroup difference	Mean 3.79 1.08 1.08 $18; Chi^2 = 3.$ $0.69 (P = 0.)$ 24.9 10.15 $95; Chi^2 = 38$ $1.73 (P = 0.)$ $70; Chi^2 = 66$ $1.88 (P = 0.)$ ces: Chi^2 = 0	9.13 13.85 58, df = 1 49) 5.78 8.6 9.38, df = 1 08) 0.04, df = 3 0.04, df = 1 0.71, df = 1	$\begin{array}{c} \textbf{Total N} \\ \textbf{Total N} \\ \textbf{79} \\ \textbf{13} \\ \textbf{92} \\ \textbf{(P = 0.0)} \\ \textbf{(P = 0.0)} \\ \textbf{35} \\ \textbf{115} \\ \textbf{(P < 0.0)} \\ \textbf{207} \\ \textbf{3} \\ \textbf{(P < 0.0)} \\ \textbf{(P = 0.0)} \\ (P =$	Mean -5.47 4.67 6); l ² = 5.6 5.1 000001) 40), l ² =	9.37 19.52 72% 6.02 8.72 ; 1 ² = 97 ; 1 ² = 95 = 0%	Total 28 14 42 80 35 115 7% 157 5%	Weight 26.9% 18.1% 45.0% 28.1% 26.9% 55.0% 100.0% (b)	Wean Difference IV, Random, 95% Cl 9.26 [5.25, 13.27] -3.59 [-16.29, 9.11] 4.31 [-7.95, 16.56] 19.30 [17.47, 21.13] 5.05 [0.99, 9.11] 12.29 [-1.67, 26.26] 8.62 [-0.35, 17.59]	-50 -25 0 25 50 Medicine Acupuncture + Medicine

FIGURE 5: Efficacy of conventional treatments plus acupuncture on (a) FEV₁ and (b) FEV₁/FVC.

	Acupunct	ure + Med	licine	М	edince			Mean Difference		Mean D	ifference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fixe	d, 95% Cl	
Lv Guifen 2012	-31.6	9.95	30	-19.9	9.72	30	60.1%	-11.70 [-16.68, -6.72]		—		
Zhu Dongxiao 2010	-61	12.53	33	-50	12.77	33	39.9%	-11.00 [-17.10, -4.90]				
Total (95% CI) Heterogeneity: Chi ² = 0 Test for overall effect: 2	0.03, df = 1 (l Z = 5.80 (P <	P = 0.86); l [;] 0.00001)	63 ² = 0%			63	100.0%	-11.42 [-15.28, -7.56]	-20	-10 Medicine	0 10	+ Medicine

FIGURE 6: Efficacy of conventional treatments plus acupuncture on IL-6 levels.

of asthma had no influence on the heterogeneity. Thus, a random-effects model was used for FEV_1 and FEV_1/FVC . Furthermore, sensitivity analysis was performed by excluding the included studies one by one, which showed that all parameters were stable. Second, only two studies including 126 patients compared the effects of IL-6 between the two groups; the sample size was too small. Fortunately, we found stable results, assuming a different model to test the sensitivity.

To the best of our knowledge, this is the first metaanalysis that has systematically estimated the effectiveness of conventional treatments plus acupuncture compared with conventional treatments alone. Conventional treatments plus acupuncture did not show any beneficial effects on pulmonary function in asthmatic patients over conventional treatments alone. However, conventional treatments plus acupuncture did show a clinically and statistically significant improvement in the symptom response rate and the IL-6 level when compared with conventional treatments alone. Thus, acupuncture has some effects on asthma, especially as an adjunctive therapy.

Further RCTs are required to confirm that acupuncture treatment has beneficial effects on alleviating symptoms and immunomodulatory activity (via inflammatory cells and cytokines) in asthma patients as a supportive therapy combined with conventional treatments. A standard method of conventional treatments plus acupuncture may be implemented in the near future.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Supplementary Materials

When searching the Chinese databases, we used Chinese key words and translated them in this article. (Supplementary Materials)

References

- D. J. Erle and D. Sheppard, "The cell biology of asthma," *The Journal of Cell Biology*, vol. 205, no. 5, pp. 621–631, 2014.
- [2] S. E. Wenzel, "Asthma phenotypes: the evolution from clinical to molecular approaches," *Nature Medicine*, vol. 18, no. 5, pp. 716–725, 2012.
- [3] J. B. Soriano, A. A. Abajobir, and K. H. Abate, "Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 2006 to 2016: A systematic analysis for the Global Burden of Disease study," *The Lancet Respiratory Medicine*, vol. 5, no. 9, pp. 691–706, 2017.
- [4] C. Janson, A. Johannessen, K. Franklin et al., "Change in the prevalence asthma, rhinitis and respiratory symptom over a 20 year period: associations to year of birth, life style and sleep related symptoms," *BMC Pulmonary Medicine*, vol. 18, no. 1, article 152, 2018.
- [5] D. A. Fedele, T. E. Barnett, R. S. Everhart, C. Lawless, and J. R. Forrest, "Comparison of asthma prevalence and morbidity among rural and nonrural youth," *Annals of Allergy, Asthma and Immunology*, vol. 117, no. 2, pp. 193.e191–194.e191, 2016.
- [6] A. Athavale, H. Iyer, A. D. Punwani et al., "Association of environmental factors, prevalence of asthma and respiratory morbidity in Mumbai: need of a public health policy," *Journal* of the Association of Physicians of India, vol. 65, no. 6, pp. 48– 54, 2017.
- [7] P. J. Gergen, H. E. Mitchell, A. Calatroni et al., "Sensitization and exposure to pets: the effect on asthma morbidity in the US population," *The Journal of Allergy and Clinical Immunology in Practice*, vol. 6, no. 1, pp. 101.e102–107.e102, 2018.
- [8] P. Kumar and U. Ram, "Patterns, factors associated and morbidity burden of asthma in India," *PLoS ONE*, vol. 12, no. 10, Article ID e0185938, 2017.
- [9] E. Morales-Raveendran, E. Goodman, E. West et al., "Associations between asthma trigger reports, mental health conditions, and asthma morbidity among world trade center rescue and recovery workers," *The Journal of Asthma*, pp. 1–8, 2018.
- [10] T. D. Wu, E. P. Brigham, R. Peng et al., "Overweight/obesity enhances associations between secondhand smoke exposure

- [11] O. Boyman, C. Kaegi, M. Akdis et al., "EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders," *Allergy*, vol. 70, no. 7, pp. 727–754, 2015.
- [12] O. Palomares, S. Sánchez-Ramón, I. Dávila et al., "dIvergEnt: How IgE axis contributes to the continuum of allergic asthma and anti-IgE therapies," *International Journal of Molecular Sciences*, vol. 18, no. 6, 2017.
- [13] K. J. Hetherington and L. G. Heaney, "Drug therapies in severe asthma-the era of stratified medicine," *Clinical Medicine*, vol. 15, no. 5, pp. 452–456, 2015.
- [14] D. Price, M. Fletcher, and T. Van Der Molen, "Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey," *NPJ Primary Care Respiratory Medicine*, vol. 24, article 14009, 2014.
- [15] P. J. Barnes, "New therapies for asthma: is there any progress?" *Trends in Pharmacological Sciences*, vol. 31, no. 7, pp. 335–343, 2010.
- [16] "Use of acupuncture in modern health care," WHO chronicle, vol. 34, no. 7-8, pp. 294–301, 1980.
- [17] P. L. R. Dias, S. Subramaniam, and N. D. W. Lionel, "Effects of acupuncture in bronchial asthma: preliminary communication," *Journal of the Royal Society of Medicine*, vol. 75, no. 4, pp. 245–248, 1982.
- [18] D. P. Tashkin, R. J. Kroening, D. E. Bresler, M. Simmons, A. H. Coulson, and H. Kerschnar, "A controlled trial of real and simulated acupuncture in the management of chronic asthma," *The Journal of Allergy and Clinical Immunology*, vol. 76, no. 6, pp. 855–864, 1985.
- [19] K. P. Fung, O. K. Chow, and S. Y. So, "Attenuation of exerciseinduced asthma by acupuncture," *Lancet*, vol. 2, no. 8521-8522, pp. 1419–1422, 1986.
- [20] J. Martin, A. N. A. Donaldson, R. Villarroel, M. K. B. Parmar, E. Ernst, and I. J. Higginson, "Efficacy of acupuncture in asthma: Systematic review and meta-analysis of published data from 11 randomised controlled trials," *European Respiratory Journal*, vol. 20, no. 4, pp. 846–852, 2002.
- [21] Y. Fu, Z. H. Liu, B. K. Wang et al., "Effects of acupuncture on lung function in patients with bronchial asthma," *Chinese Journal of Basic Medicine of Traditional Chinese Medicine*, vol. 20, no. 3, pp. 364–367, 2014.
- [22] Z.-L. Zhang, X.-Q. Ji, L. Xue, and S.-H. Yu, "Clinical observation on acupuncture for treatment of bronchial asthma at acute stage," *Chinese Acupuncture and Moxibustion*, vol. 25, no. 3, pp. 158–160, 2005.
- [23] D. X. Zhu, "Effects of acupuncture and drug application on bronchial asthma and the effects on cytokines," *Shanghai Journal of Acupuncture*, vol. 29, no. 2, pp. 91–93, 2010.
- [24] J.-Y. Choi, H.-J. Jung, J.-I. Kim et al., "A randomized pilot study of acupuncture as an adjunct therapy in adult asthmatic patients," *The Journal of Asthma*, vol. 47, no. 7, pp. 774–780, 2010.
- [25] W.-P. Zhang, "Effects of acupuncture on clinical symptoms and pulmonary function in the patient of bronchial asthma," *Chinese Acupuncture and Moxibustion*, vol. 26, no. 11, pp. 763–767, 2006.
- [26] G. F. Lu, "Curative effect of acupuncture combined with medicine in treating bronchial asthma," *Chinese Journal of Practical Medicine*, vol. 16, pp. 23-24, 2012.

- [27] W. Y. Wang, "Therapeutic effect of acupuncture on 35 cases of bronchial asthma," *Jilin Medical*, vol. 26, pp. 4462-4463, 2010.
- [28] S. Q. Jiang, "Observation of the curative effect of combined Chinese and western medicine in the treatment of acute attacks of asthma," *Chinese Contemporary Medicine*, vol. 19, no. 1, pp. 99-100, 2012.
- [29] X. Z. Jin, *Clinical Research of "Combination of Back-shu and Front-Mu points" in the Treatment of Bronchial Asthma*, Nanjing University of Traditional Chinese Medicine, 2013.
- [30] Y. D. Xu, J. M. Cui, Y. Wang et al., "Proteomic analysis reveals the deregulation of inflammation-related proteins in acupuncturetreated rats with asthma onset," *Evidence-Based Complementary and Alternative Medicine*, vol. 2012, Article ID 850512, 14 pages, 2012.